ikon ONCOFoCUS

1.6 by Portable Medical Technology Ltd.


Mar 3, 2019

Tentang ONCOFoCUS

Indonesia

FN app menilai jika pasien berisiko febrile neutropenia.

ONCOFoCUS Febrile Neutropenia Risk Assessment. The application allows you to assess if a patient undergoing chemotherapy is at risk of febrile neutropenia. Through a series of standardised questions based on EORTC and NCCN guidelines, the tool asks you to consider the numerous factors that may contribute to an increased risk.

Benefits

· It allows you to reference the EORTC and NCCN estimated risk associated with Febrile Neutropenia across all of the major chemotherapy regimes.

·All of the content is accessible via your mobile device, this means you can access the content “on the go”, to allow for fast, efficient decision making.

- The results of your assessments can be shared with colleagues via PDF and saved within the history section of the application. This facilitates collaboration with your colleagues.

ONCOFoCUS This tool is offered to you as a part of Teva's OncoFocus initiative. OncoFocus (Zoom on people) is our commitment to support the patient and the Healthcare professional across the continuum of care throughout the patient journey.

Apa yang baru dalam versi terbaru 1.6

Last updated on Mar 3, 2019

Text changes for the Australian market.

Terjemahan Memuat...

Informasi APL tambahan

Versi Terbaru

Permintaan ONCOFoCUS Update 1.6

Diunggah oleh

Nurlina Afriany

Perlu Android versi

Android 4.0+

Available on

Mendapatkan ONCOFoCUS di Google Play

Tampilkan Selengkapnya

ONCOFoCUS Tangkapan layar

Komentar Loading...
Bahasa
Bahasa
Cari...
Berlangganan APKPure
Jadilah yang pertama mendapatkan akses ke rilis awal, berita, dan panduan dari game dan aplikasi Android terbaik.
Tidak, terima kasih
Mendaftar
Berlangganan dengan sukses!
Anda sekarang berlangganan APKPure.
Berlangganan APKPure
Jadilah yang pertama mendapatkan akses ke rilis awal, berita, dan panduan dari game dan aplikasi Android terbaik.
Tidak, terima kasih
Mendaftar
Kesuksesan!
Anda sekarang berlangganan buletin kami.